Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions of PSMA antibodies

a technology of psma antibodies and antibodies, which is applied in the field of cancer-associated polypeptides and antibodies, can solve the problems of increasing health care expenditure, affecting the treatment effect, and affecting the treatment effect, and achieving the effect of assessing the effectiveness of a treatmen

Inactive Publication Date: 2008-11-20
AMGEN FREMONT INC +1
View PDF99 Cites 145 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0038]In another aspect of the invention, methods for assessing the effectiveness of a treatment of a subject with a PSMA-mediated disease are provided. The methods include administering to a subject suspected treated for a PSMA-mediated disease an effective amount of the foregoing antibodies or antigen-binding fragments thereof, allowing the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA, and detecting the formation of the complex to the target epitope. The amount of the complex in the subject suspected of having or previously diagnosed with PSMA-mediated disease is indicative of the effectiveness of the treatment.

Problems solved by technology

Thus, prostate cancer also represents a major cause of suffering and increased health care expenditures.
Historically, the drawback of this procedure is that most cancers had spread beyond the bounds of the operation by the time they were detected.
Patients with bulky, high-grade tumors are less likely to be successfully treated by radical prostatectomy.
Diethylstilbestrol from estrogen is another useful hormonal therapy which has a disadvantage of causing cardiovascular toxicity.
As a result, it blocks the effect of testosterone, increasing serum testosterone concentrations and allows patients to remain potent—a significant problem after radical prostatectomy and radiation treatments.
Cytotoxic chemotherapy is largely ineffective in treating prostate cancer.
Its toxicity makes such therapy unsuitable for elderly patients.
Unfortunately, almost all tumors become hormone-resistant and progress rapidly in the absence of any effective therapy.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions of PSMA antibodies
  • Compositions of PSMA antibodies
  • Compositions of PSMA antibodies

Examples

Experimental program
Comparison scheme
Effect test

example 1

Generation of a Panel of Monoclonal Antibodies (mAbs) to Conformational Epitopes on PSMA

[0266]A panel of anti-PSMA mAbs that represent promising candidates for therapy was created. Briefly, the mAbs were generated as follows: BALB / c mice were immunized subcutaneously with recombinant PSMA at approximately three-week intervals. After a total of 4 injections, mice were sacrificed and their splenocytes fused with a myeloma cell line using standard techniques in order to create hybridomas. Individual hybridoma supernatants were screened by ELISA for reactivity with PSMA derived from either LNCaP human prostate tumor cells or from 3T3 cells engineered to express full-length human PSMA (3T3-PSMA cells). Positive clones were secondarily screened by flow cytometry for specific reactivity with intact 3T3-PSMA and LNCaP cells so as to select antibodies that recognize native, cell-surface PSMA and thus have the greatest therapeutic potential.

[0267]Mice having the ability to produce human antib...

example 2

Production of Anti-PSMA mAbs

[0273]To accurately and quantitatively assess the therapeutic potential of these mAbs, the mAbs are produced in a quantity and quality suitable for extensive in vitro and in vivo characterization. Briefly, the mAb-secreting hybridomas are cultured in roller bottles in DMEM / F12 medium supplemented with 10% FBS that has been depleted of bovine IgG (Life Technologies). During the production phase of the culture, cells are maintained at ˜5×106 cells / mL via twice-weekly exchanges of media. Collected media are clarified by filtration through a 0.22 micron filter and stored at −95° C. prior to purification. Given an average antibody expression levels of 25 mg / L, approximately 3 L of roller bottle supernatants are required for each antibody to allow for losses in purification.

[0274]Culture supernatants from a given hybridoma are pooled and loaded onto a Protein A Sepharose affinity column. Mouse IgG2a, mouse IgG2b and human IgG1 antibodies are loaded directly, bu...

example 3

Evaluation of the Therapeutic Potential of the Unlabeled mAbs In Vitro

[0275]Purified mAbs are tested in a battery of assays for therapeutically relevant properties, including affinity, specificity, enzyme inhibitory activity and effector functions. The ideal product candidate binds and inhibits PSMA activity at subnanomolar concentrations and mediates potent cell-killing through Fc-related effector functions.

[0276]First, the mAbs' affinity for cell-surface and secreted forms of PSMA is measured by flow cytometry and ELISA, respectively. In the flow cytometry assay, varying amounts of mAbs are incubated with 5×105 3T3-PSMA cells in FACS buffer (PBS containing 1% FBS and 0.1% NaN3) for 2 hr to allow for saturation binding. Cells are washed and incubated with a phycoerythrin-coupled goat antibody to mouse IgG (ICN / Cappel) for detection of bound mAb by flow cytometry. Specific binding is calculated by subtracting the fluorescence intensity observed with parental 3T3 cells.

[0277]For ELIS...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Volumeaaaaaaaaaa
Volumeaaaaaaaaaa
Login to View More

Abstract

The invention includes antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, compositions containing one or a combination of such antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment. The invention also includes oligomeric forms of PSMA proteins, compositions comprising the multimers, and antibodies that selectively bind to the multimers.

Description

RELATED APPLICATIONS[0001]This application is a divisional of U.S. patent application Ser. No. 10 / 395,894, filed on Mar. 21, 2003, currently pending, which is a continuation-in-part of International application PCT / US02 / 33944 designating the United States, filed on Oct. 23, 2002, now published, which claims the benefit under 35 U.S.C. § 119 of U.S. provisional application 60 / 335,215, filed Oct. 23, 2001, now expired, U.S. provisional application 60 / 362,747, filed Mar. 7, 2002, now expired, and U.S. provisional application 60 / 412,618, filed Sep. 20, 2002, now expired, the contents of each of which are incorporated herein by reference in their entirety.FIELD OF THE INVENTION[0002]This invention relates generally to the field of cancer associated polypeptides and antibodies that recognize native epitopes on the polypeptides. In particular, the invention relates in part to antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracell...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/395C07K16/30C12N15/63G01N33/574C12N5/00A61K31/7088G01N33/50A61K38/00A61K38/21A61K39/395A61K45/00A61K47/48A61K48/00A61K51/10A61P31/12A61P35/00A61P37/02A61P37/04A61P43/00C07K14/705C07K16/28C07K16/46C12N1/15C12N1/19C12N1/21C12N5/10C12N15/09C12P21/08C12Q1/02C12Q1/34C12Q1/37G01N33/15
CPCA61K47/48469A61K47/48638A61K51/1072A61K51/1096A61K2039/505C07K16/3069C07K2317/21C07K2317/565C07K2317/622A61K47/6825A61K47/6869A61P13/08A61P31/12A61P35/00A61P37/02A61P37/04A61P43/00A61P9/00
Inventor MADDON, PAUL J.DONOVAN, GERALD P.OLSON, WILLIAM C.SCHUELKE, NORBERTGARDNER, JASONMA, DANGSHEKANG, JASPAL S.GREEN, LARRY
Owner AMGEN FREMONT INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com